Abstract
Regulators, drug companies, academic scientists, bioethicists, clinicians and, increasingly, the general public are starting to realize that pharmacogenetics (PGx) will probably have a huge impact on the way in which we treat both common and rare diseases. But how much thought has gone into the ethical issues that the incorportation of phamacogenetic testing into drug discovery, prescription and use will entail? It seems that “quite a bit” is the answer, as the diverse viewpoints of representatives of all of these groups presented here illustrate. However, these views also highlight that now is the time to start formulating and implementing solutions to these potential problems.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Related links
Rights and permissions
About this article
Cite this article
Breckenridge, A., Lindpaintner, K., Lipton, P. et al. Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 5, 676–680 (2004). https://doi.org/10.1038/nrg1431
Issue Date:
DOI: https://doi.org/10.1038/nrg1431
- Springer Nature Limited
This article is cited by
-
Attitudes of Health Care Professionals Toward Pharmacogenetic Testing
Molecular Diagnosis & Therapy (2011)
-
Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees
The Pharmacogenomics Journal (2009)
-
Ancillary risk information and pharmacogenetic tests: social and policy implications
The Pharmacogenomics Journal (2008)
-
Personalized Medicine Europe: Health, Genes and Society: Tel-Aviv University, Tel-Aviv, Israel, June 19–21, 2005
European Journal of Human Genetics (2006)
-
A call for the creation of personalized medicine databases
Nature Reviews Drug Discovery (2006)